UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

The pound was quoted at USD1.3366 early on Friday in London, compared to USD1.3412 at the equities close on Thursday. The euro stood at USD1.1135, lower against USDUSD1.1179. Against the yen, the ...

Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.

Phathom Pharmaceuticals developed Voquezna, a first-in-class PCAB, licensed from Takeda, for acid-related disorders. Find out ...

Despite revenue and cash flow declines, Franco-Nevada reported record margins with an 88.7% cash margin, benefiting from ...

Shares of The Allstate Corp. (ALL) have gained as much as 35% so far this year. Investors who’ve enjoyed this rally wonder if ...

The water industry is set for substantial growth as increasing water scarcity drives demand for water-related infrastructure ...

Westlife Foodworld shares soared, driven by a surge in trading volume, as the company grapples with a challenging operating ...

A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo The U.S. FDA approved Bristol Myers Squibb's schizophrenia ...